Literature DB >> 29324586

Ten-year experience of transjugular intrahepatic portosystemic shunt for noncirrhotic portal hypertension.

David Regnault1, Louis d'Alteroche1, Charlotte Nicolas1, Fanny Dujardin2, Jean Ayoub3, Jean Marc Perarnau1.   

Abstract

BACKGROUND: Transjugular intrahepatic portosystemic shunt (TIPS) is considered to be well suited for the treatment of noncirrhotic portal hypertension (NCPHT) because of a usually severe portal hypertension (PHT) and a mild liver failure, but very less data are available. PATIENTS AND METHODS: Records of patients referred for TIPS between 2004 and 2015 for NCPHT were reviewed. No patient should have clinical or biological or histological features of cirrhosis.
RESULTS: Twenty-five patients with a wide variety of histological lesions (sinusoidal dilatations, granulomatosis, regenerative nodular hyperplasia, obliterative portal venopathy, or subnormal liver) and a wide variety of associated diseases (thrombophilia, sarcoidosis, common variable immunodeficiency, scleroderma, Castleman's disease, early primitive biliary cirrhosis, congenital liver fibrosis, chemotherapy, purinethol intake, and congenital varices) were included. Two complications occurred during the procedure: one periprosthetic hematoma and the other misposition of a covered stent. During the first month, two other patients had an early thrombosis, another had induced encephalopathy, and one died of early rebleeding. Two of these complications occurred in patients with cavernoma. With a mean follow-up of 39 months, 10 patients experienced at least one episode of spontaneous encephalopathy, with three of these patients requiring a stent reduction. Five patients had a recurrence of their initial symptoms, and one had an asymptomatic hemodynamic dysfunction.
CONCLUSION: TIPS is effective in NCPHT but can be technically difficult, especially in the case of cavernoma. Good liver function does not prevent the occurrence of long-term encephalopathy.

Entities:  

Mesh:

Year:  2018        PMID: 29324586     DOI: 10.1097/MEG.0000000000001067

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  International multicenter experience of transjugular intrahepatic portosystemic shunt implantation in patients with common variable immunodeficiency.

Authors:  Anna-Maria Globig; Maximilian Heeg; Carsten Schade Larsen; Ruben Duarte Ferreira; Gerhard Kindle; Sigune Goldacker; Valentina Strohmeier; Susana L Silva; Charlotte Cunningham-Rundles; Isabella Quinti; Robert Thimme; Dominik Bettinger; Michael Schultheiß; Klaus Warnatz
Journal:  J Allergy Clin Immunol Pract       Date:  2021-03-13

Review 2.  Common variable immune deficiency: Dissection of the variable.

Authors:  Charlotte Cunningham-Rundles
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

3.  Sleeve Gastrectomy: You Might Lose your Liver!

Authors:  J Danion; L Genser; O Scatton
Journal:  Obes Surg       Date:  2019-01       Impact factor: 4.129

4.  Refractory Hepatic Hydrothorax: A Rare Complication of Systemic Sclerosis and Presinusoidal Portal Hypertension.

Authors:  Gary A Abrams; Robert Chapman; Samuel R W Horton
Journal:  Case Reports Hepatol       Date:  2018-04-30

5.  Relationship between hemodynamic parameters and portal venous pressure in cirrhosis patients with portal hypertension.

Authors:  Hongjuan Yao; Yongliang Wang
Journal:  Open Life Sci       Date:  2020-12-31       Impact factor: 0.938

6.  Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction.

Authors:  Florent Artru; Naik Vietti-Violi; Christine Sempoux; Joana Vieira Barbosa; Fabio Becce; Nelly Sah; Astrid Marot; Pierre Deltenre; Eleni Moschouri; Montserrat Fraga; Arnaud Hocquelet; Rafael Duran; Darius Moradpour; Pierre-Emmanuel Rautou; Alban Denys
Journal:  JHEP Rep       Date:  2022-05-25

Review 7.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

8.  Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.

Authors:  Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; Simon Travis; Matthew J Armstrong; Emmanuel A Tsochatzis; Ian A Rowe; Nicholas Roslund; Hamish Ireland; Mandy Lomax; Joanne A Leithead; Homoyon Mehrzad; Richard J Aspinall; Joanne McDonagh; David Patch
Journal:  Gut       Date:  2020-02-29       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.